Fig. 11.
Docking poses in the cavity of NSP3 for top 10 compounds and Redesivir and its parent compound (GS-441524); (a) (top 1) Folic acid, (b) (top 2) Telmisartann, (c) (top 3) Methotrexate, (d) (top 4) Bosentan, (e) (top 5) Lapatinib, (f) (top 6) Gefitinib, (g) (top 7) Ketoconazole, (h) (top 8) Carvedilol, (i) (top 9) Glyburide, (j) (top 10) Avanafil, (k) (refernce) Remdesivir, and (l) (reference) GS-441524